Stephen Croke

Stephen Croke

Auto-generated profile, based on publicly available information

Stephen Croke

Edinburgh Cancer Research Institute of Genetics & Cancer University of Edinburgh Crewe Road South Edinburgh EH4 2XR UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
CACecilia C. Ayala-Aguilera
Cecilia C. Ayala-Aguilera
TVTeresa Valero
Teresa Valero
ALAlvaro Lorente-Macias
Alvaro Lorente-Macias
DBDaniel J. Baillache
Daniel J. Baillache
SCStephen Croke
Stephen Croke
AUAsier Unciti-Broceta
Asier Unciti-Broceta
The central role of dysregulated kinase activity in the etiology of progressive disorders, including cancer, has fostered incremental efforts on drug discovery programs over the past 40 years. As a result, kinase inhibitors are today one of the most important classes of drugs. The FDA approved 73 small molecule kinase inhibitor drugs until September 2021, and additional inhibitors were approved by other regulatory agencies during that time. To complement the published literature on clinical kinase inhibitors, we have prepared a review that recaps this large data set into an accessible format for the medicinal chemistry community. Along with the therapeutic and pharmacological properties of each kinase inhibitor approved across the world until 2020, we provide the synthesis routes originally used during the discovery phase, many of which were only available in patent applications. In the last section, we also provide an update on kinase inhibitor drugs approved in 2021.

16 April 2024 in Chemistry – A European Journal
Verified
Journal Article
Open access
PDF file
MLMelissa van de L'ISle
Melissa van de L'ISle
SCStephen Croke
Stephen Croke
TVTeresa Valero
Teresa Valero
AUAsier Unciti-Broceta
Asier Unciti-Broceta
Transition‐metal‐catalyzed bioorthogonal reactions emerged a decade ago as a novel strategy to implement spatiotemporal control over enzymatic functions and pharmacological interventions. The use of this methodology in experimental therapy is driven by the ambition of improving the tolerability and PK properties of clinically‐used therapeutic agents. The preclinical potential of bioorthogonal catalysis has been validated in vitro and in vivo with the in situ generation of a broad range of drugs, including cytotoxic agents, anti‐inflammatory drugs and anxiolytics. In this article, we report our investigations towards the preparation of solid‐supported Cu(I)‐microdevices and their application in bioorthogonal uncaging and click reactions. A range of ligand‐functionalized polymeric devices and off‐on Cu(I)‐sensitive sensors were developed and tested under conditions compatible with life. Last, we present a preliminary exploration of their use for the synthesis of PROTACs through CuAAC assembly of two heterofunctional mating units.

2 October 2024
Verified
Book Chapter
Closed access
PDF file
CAC. Adam
C. Adam
ALAlvaro Lorente-Macias
Alvaro Lorente-Macias
SCS. Croke
S. Croke
AUAsier Unciti-Broceta
Asier Unciti-Broceta
The bioorthogonal synthesis of drugs offers a unique opportunity for targeting — either molecularly, spatiotemporally or both — the delivery of active compounds directly to the disease site. Problems such as unfavorable pharmacokinetic (PK) profiles and dose-limiting side effects can be mitigated with the careful deployment of the tools of biorthogonal chemistry. In order to access medicinal applications, researchers have developed groundbreaking new chemistries for the caging and uncaging, assembly, and molecular targeting of a wide range of clinically approved drugs. This review presents notable examples of bioorthogonal drug synthesis that have emerged from the two main branches of the bioorthogonal field: organic click chemistries and transition-metal-catalyzed reactions.